ACT Brief: Neutral Tech Adoption at Sites, Scaling Unstructured Data for eSource, and Novo Nordisk’s CagriSema NDA

from Applied Clinical Trials · host Applied Clinical Trials

In today’s ACT Brief, we examine how sponsors are reassessing new engagement technologies to avoid increasing site burden, review new research on integrating unstructured health data to scale eSource-enabled trials, and cover Novo Nordisk’s NDA submission for its fixed-dose amylin–GLP-1 obesity therapy, CagriSema.

Episode metadata supplied by the publisher feed · Published Dec 19, 2025

Embed this episode

Attribution link and audio player

Ready to play

ACT Brief: Neutral Tech Adoption at Sites, Scaling Unstructured Data for eSource, and Novo Nordisk’s CagriSema NDA

0:00 2:21

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Applied Clinical Trials?

This episode is 2 minutes long.

When was this Applied Clinical Trials episode published?

This episode was published on December 19, 2025.

Can I download this Applied Clinical Trials episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!